Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $69 from $115 and keeps an Overweight rating on the shares. The firm notes ...

Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Applied Materials tumbles after issuing a disappointing fiscal first-quarter outlook, Palantir is transferring its stock listing to the Nasdaq, and Tesla rises following a decline on worries President ...

Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and ...

Super Micro Computer, Inc. SMCI stock tumbled 24.23% after the company recently announced it could not file its quarterly ...

Big pharma stocks needed a shot in the arm after Donald Trump chose vaccine skeptic Robert F. Kennedy Jr. as health secretary ...

Shares of vaccine-makers fell after reports that Donald Trump is expected to nominate vaccine skeptic Robert F. Kennedy Jr.

Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.

Vaccine stocks slid late Thursday as reports stated noted anti-vaccine politician Robert Kennedy Jr. will serve as the next ...

Shares of vaccine makers such as Moderna (MRNA) and Pfizer (PFE) have plunged on news that president-elect Donald Trump has ...